Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Live in Patients With Essential Hypertension (MicCAT)

Boehringer Ingelheim

Status and phase: Completed; Phase 4

Conditions: Hypertension

Treatments: Drug: High dose of telmisartan; Drug: Low dose of telmisartan

Study type: Interventional

Funder types: Industry

Identifiers

NCT02242370

502.461

Details and patient eligibility

About

Study to assess the effect of Telmisartan on diastolic and systolic blood pressure and to establish the effect on patient's quality of life scores.

Enrollment: 3,045 patients

Sex: All

Ages: 20 to 93 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with Stage I essential Hypertension (diastolic blood pressure 90-99 mmHg, and/or systolic blood pressure 140-159 mmHg)
• Signed informed consent form

Exclusion criteria

• Females of childbearing potential

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

3,045 participants in 2 patient groups

Telmisartan low dose

Experimental group

Treatment:

Drug: Low dose of telmisartan

Telmisartan high dose

Experimental group

Treatment:

Drug: High dose of telmisartan